Quality of life and associated factors among HIV positive patients after completion of treatment for Cryptococcal meningitis.
AIDS-Related Opportunistic Infections
/ drug therapy
Adult
Africa
Anti-Inflammatory Agents
/ therapeutic use
Antifungal Agents
/ therapeutic use
Asia
Body Weight
Dexamethasone
/ therapeutic use
Drug Therapy, Combination
Female
HIV Infections
/ complications
Humans
Male
Meningitis, Cryptococcal
/ complications
Middle Aged
Quality of Life
Treatment Outcome
Journal
PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
16
06
2020
accepted:
13
11
2020
revised:
15
03
2021
pubmed:
4
3
2021
medline:
25
6
2021
entrez:
3
3
2021
Statut:
epublish
Résumé
Cryptococcal meningitis (CCM) remains one of the leading causes of mortality among HIV infected patients. Due to factors such as the severity of CCM pathology, the quality of life (QOL) of patients post-treatment is likely to be poor. Few studies have reported on QOL of CCM patients post treatment completion. We used data collected among patients in the CryptoDex trial (ISRCTN59144167) to determine QOL and associated factors at week 10 and six months from treatment initiation. CryptoDex was a double-blind placebo-controlled trial of adjunctive dexamethasone in HIV infected adults with CCM, conducted between 2013 and 2015 in six countries in Asia and Africa. QOL was determined using the descriptive and Visual Analog Scales (VAS) of the EuroQol Five-Dimension-Three-Level (EQ-5D-3L) tool. We derived index scores, and described these and the VAS scores at 10 weeks and 6 months; and used linear regression to determine the relationship between various characteristics and VAS scores at both time points. VAS scores were interpreted as very good (81-100), good (51-80), normal (31-50) and bad/very bad (0-30). Of 451 patients enrolled in the trial, 238 had QOL evaluations at week 10. At baseline, their mean age (SD) was 35.2(8.5) years. The mean index scores (SD) were 0.785(0.2) and 0.619(0.4) among African and Asian patients respectively at week 10, and 0.879(0.2) and 0.731(0.4) among African and Asian patients respectively at month six. The overall mean VAS score (SD) at 10 weeks was 57.2 (29.7), increasing significantly to 72(27.4) at month six (p<0.001). At week 10, higher VAS score was associated with greater weight (p = 0.007) and being African (p<0.001), while lower VAS score was associated with positive yeast culture at day 14 (p = 0.026). At month six, higher VAS score remained associated with African origin (p = 0.006) while lower VAS score was associated with positive yeast culture (p = 0.006). Lower VAS scores were associated with higher number of inpatient days at 10 weeks and 6 months (p = 0.003 and 0.002 respectively). QOL was good among patients that had completed therapy for CCM, but below perfect. Strategies to improve QOL among CCM survivors are required.
Sections du résumé
BACKGROUND
Cryptococcal meningitis (CCM) remains one of the leading causes of mortality among HIV infected patients. Due to factors such as the severity of CCM pathology, the quality of life (QOL) of patients post-treatment is likely to be poor. Few studies have reported on QOL of CCM patients post treatment completion. We used data collected among patients in the CryptoDex trial (ISRCTN59144167) to determine QOL and associated factors at week 10 and six months from treatment initiation.
METHODOLOGY
CryptoDex was a double-blind placebo-controlled trial of adjunctive dexamethasone in HIV infected adults with CCM, conducted between 2013 and 2015 in six countries in Asia and Africa. QOL was determined using the descriptive and Visual Analog Scales (VAS) of the EuroQol Five-Dimension-Three-Level (EQ-5D-3L) tool. We derived index scores, and described these and the VAS scores at 10 weeks and 6 months; and used linear regression to determine the relationship between various characteristics and VAS scores at both time points. VAS scores were interpreted as very good (81-100), good (51-80), normal (31-50) and bad/very bad (0-30).
RESULTS
Of 451 patients enrolled in the trial, 238 had QOL evaluations at week 10. At baseline, their mean age (SD) was 35.2(8.5) years. The mean index scores (SD) were 0.785(0.2) and 0.619(0.4) among African and Asian patients respectively at week 10, and 0.879(0.2) and 0.731(0.4) among African and Asian patients respectively at month six. The overall mean VAS score (SD) at 10 weeks was 57.2 (29.7), increasing significantly to 72(27.4) at month six (p<0.001). At week 10, higher VAS score was associated with greater weight (p = 0.007) and being African (p<0.001), while lower VAS score was associated with positive yeast culture at day 14 (p = 0.026). At month six, higher VAS score remained associated with African origin (p = 0.006) while lower VAS score was associated with positive yeast culture (p = 0.006). Lower VAS scores were associated with higher number of inpatient days at 10 weeks and 6 months (p = 0.003 and 0.002 respectively).
CONCLUSION
QOL was good among patients that had completed therapy for CCM, but below perfect. Strategies to improve QOL among CCM survivors are required.
Identifiants
pubmed: 33657099
doi: 10.1371/journal.pntd.0008983
pii: PNTD-D-20-01073
pmc: PMC7959361
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Antifungal Agents
0
Dexamethasone
7S5I7G3JQL
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0008983Subventions
Organisme : Medical Research Council
ID : MC_UU_00027/1
Pays : United Kingdom
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
PLoS One. 2015 Jun 03;10(6):e0126810
pubmed: 26039733
N Engl J Med. 2016 Feb 11;374(6):542-54
pubmed: 26863355
Value Health. 2011 Dec;14(8):1142-5
pubmed: 22152185
Clin Epidemiol. 2014 May 13;6:169-82
pubmed: 24872723
J Gen Intern Med. 2005 Jan;20(1):21-7
pubmed: 15693923
Ann Intern Med. 2011 Aug 16;155(4):209-16
pubmed: 21768555
N Engl J Med. 2018 Mar 15;378(11):1004-1017
pubmed: 29539274
Lancet Infect Dis. 2017 Aug;17(8):873-881
pubmed: 28483415
J Infect. 2001 Nov;43(4):226-33
pubmed: 11869059
Health Qual Life Outcomes. 2018 Sep 24;16(1):194
pubmed: 30249245
N Engl J Med. 2013 Apr 4;368(14):1291-1302
pubmed: 23550668
Arch Public Health. 2014 Nov 17;72(1):40
pubmed: 25671112
Curr Clin Microbiol Rep. 2016;3:92-102
pubmed: 27257597
Clin Infect Dis. 2014 Mar;58(5):736-45
pubmed: 24319084
Lancet Infect Dis. 2014 Apr;14(4):281-90
pubmed: 24602844
JAMA. 2002 Dec 18;288(23):3027-34
pubmed: 12479768
PLoS One. 2019 Jan 30;14(1):e0210287
pubmed: 30699151
Popul Health Metr. 2003 Dec 16;1(1):11
pubmed: 14678566
Trials. 2014 Nov 12;15:441
pubmed: 25391338
Clin Infect Dis. 2008 Jun 1;46(11):1694-701
pubmed: 18433339
Clin Infect Dis. 1999 Jan;28(1):82-92
pubmed: 10028076
Open Forum Infect Dis. 2015 Dec 28;2(4):ofv157
pubmed: 26716103
F1000Res. 2019 May 28;8:
pubmed: 31275560
AIDS. 2009 Feb 20;23(4):525-30
pubmed: 19182676